UPHEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.89 USD | -5.32% |
|
-2.73% | +287.80% |
| 21/03 | UpHealth, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 21/03 | UpHealth, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Its low valuation, with P/E ratio at 5.93 and 2.34 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Software
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +287.80% | 16.59M | - | ||
| +27.09% | 24.31B | - | C | |
| -14.06% | 23.88B | C | ||
| +9.94% | 2.63B | D+ | ||
| -20.45% | 1.91B | - | ||
| +85.85% | 1.86B | C- | ||
| -50.22% | 1.51B | - | - | |
| +7.97% | 1.36B | - | ||
| -0.20% | 1.27B | B- | ||
| -18.38% | 1.25B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- UPHL Stock
- Ratings UpHealth, Inc.
